HIV/AIDS Basics & Prevention

Just Diagnosed

HIV Treatment

Living With HIV

AIDS Policy & Activism

HIV Around the World

Conference Coverage

Indinavir (Crixivan) Research

See also: Medication Side Effects | Drug Interactions

Hide Archived (Historical) Articles

HIV JournalView: Study Ties Insulin Resistance to NRTIs, Not PIs (September 2005)
d4T and 3TC are associated with insulin resistance and high insulin levels; indinavir is associated only with elevated insulin levels; and no link to insulin abnormalities is found for AZT or ddI.
From The Body PRO
High Dose of Vitamin C Significantly Reduces Indinavir Levels in Pilot Study (September 16, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
"Mono"-Therapy for HIV Infection Using Ritonavir-Boosted Indinavir (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Indinavir or Boosted Indinavir? (March 2002)
[Archived Article]
In Project Inform Perspective, from Project Inform
Ingrown Toenails Still a Possible Side Effect (November 2001)
[Archived Article]
Indinavir-ritonavir interaction is possible culprit.
In HIV Treatment ALERTS!, from The Center for AIDS
A Phase IV Randomized Open-Label Multicenter Trial to Evaluate Safety and Efficacy of Indinavir/Ritonavir (800/100 mg BID) vs. Saquinavir/Ritonavir (1,000/100 mg BID) in Adult HIV-1 Infection: The Max Cmin 1 Trial (October 29, 2001)
[Archived Article]
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
Lack of Clinically Relevant Drug-Drug Interactions Between Tenofovir DF and Efavirenz, Indinavir, Lamivudine and Lopinavir/Ritonavir in Healthy Subjects (October 29, 2001)
[Archived Article]
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
Differential In Vitro Effects of Indinavir, Nelfinavir and Amprenavir On Cell Differentiation, Insulin Sensitivity and Apoptosis in an Adapted Adipose Cell Model -- Preventive Impact of Rosiglitazone (October 25, 2001)
[Archived Article]
In 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO
Abacavir/Combivir Is Comparable to Indinavir/Combivir in HIV-1 Infected Antiretroviral Therapy Naive Adults: Preliminary Results of a 48-Week Open-Label Study (CNA3014) (July 10, 2001)
[Archived Article]
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Therapeutic Drug Monitoring (TDM) of Nelfinavir (NFV) and Indinavir (IDV) In Treatment-Naive Patients Improves Therapeutic Outcome After 1 Year: Results from ATHENA (July 9, 2001)
[Archived Article]
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
High Blood Pressure With Indinavir (May 25, 2001)
[Archived Article]
From Canadian AIDS Treatment Information Exchange
Protease Combinations: Ritonavir and Indinavir One Year Later (March 15, 2001)
[Archived Article]
Developments from the 8th Conference on Retroviruses and Opportunistic Infections.
From Canadian AIDS Treatment Information Exchange
ACTG 5056: Metabolic Status and Cardiovascular Disease Risk for a Cohort of HIV-1-Infected Persons Durably Suppressed on an Indinavir-Containing Regimen (ACTG 372A) (February 7, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Indinavir/Ritonavir Versus Indinavir in Combination With AZT/3TC for Treatment of HIV in Nucleoside-Experienced Patients: A Randomized, Open-Label Trial (February 6, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Preliminary Results From Indinavir (IDV) and Ritonavir (RTV) in a Once-Daily Regimen (Marck 103/104) (February 6, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Is Once Daily Indinavir With Ritonavir On the Way? (December 20, 2000)
[Archived Article]
From Canadian AIDS Treatment Information Exchange
Saliva Useful for Monitoring Indinavir Levels in HIV-Infected Patients (October 2000)
In Body Positive, from Body Positive
Abacavir vs. Indinavir in Therapy-Naive People (CNA3014) (August 17, 2000)
[Archived Article]
In STEP Ezine, from Seattle Treatment Education Project
Ritonavir Intensification of Indinavir in People Without Complete HIV Suppression (August 17, 2000)
[Archived Article]
In STEP Ezine, from Seattle Treatment Education Project
A Randomized, Controlled, Open-label Study Comparing the Adherence and Convenience of Continuing Indinavir Q8H vs. Switching to Norvir/Indinavir 400 mg/400 mg BID (The NICE Study) (July 12, 2000)
In The XIII International AIDS Conference, from The Body PRO
Long-Term Comparative Outcomes of Indinavir (IDV) vs. Nelfinavir (NFV)-Based HAART in Naive Patients in Routine Clinical Practice (July 12, 2000)
[Archived Article]
The Body's Coverage of the XIII International AIDS Conference.
In The XIII International AIDS Conference, from The Body PRO
Once-a-Day Indinavir Therapy in Virologically Controlled HIV-Positive Persons (July 11, 2000)
In The XIII International AIDS Conference, from The Body PRO
Viral Rebound in the Presence of Indinavir Without Protease Inhibitor Resistance (February 4, 1999)
[Archived Article]
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Co-Administration of Indinavir 1200 mg with Nelfinavir 1250 mg in a Twice Daily Regimen: Preliminary Safety, PK Activity (February 2, 1999)
[Archived Article]
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Co-Administration of Indinavir 1,200 mg (IDV) and Nelfinavir (NFV) 1,250 mg in a Twice Daily Regimen: Preliminary Safety, Pharmacokinetic (PK) and Anti-Viral Activity (November 14, 1998)
[Archived Article]
In The 36th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
Indinavir 12 Hour Dosing an Alternative to 8 Hourly Dosing Regimen: A Pilot Study (July 3, 1998)
[Archived Article]
In The 12th International AIDS Conference, from The Body PRO
Two-Year Durability of HIV-1 Viral Load Suppression in Patients Treated With Indinavir Who Experience Virus Load Declines to <500 VRNA Copies/mL (June 29, 1998)
[Archived Article]
In The 12th International AIDS Conference, from The Body PRO
Efavirenz + Indinavir (February 4, 1998)
[Archived Article]
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Antiviral Activity and Acceptance of Two Different Triple Combinations (February 3, 1998)
[Archived Article]
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Combination Therapy With AZT + 3TC + Indinavir vs. d4T + 3TC + Indinavir in Pretreated Patients With Less Than 200 CD4/mm³ (February 3, 1998)
[Archived Article]
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Indinavir Pharmacokinetics and Menstrual Cycle Physiology (February 3, 1998)
[Archived Article]
From Seattle Treatment Education Project
The START Trials (February 3, 1998)
[Archived Article]
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Thirty-Two Week Follow-Up of Indinavir Sulfate Administered Q8 Hours Versus Q12 in Combination With Zidovudine and Lamivudine (February 3, 1998)
[Archived Article]
From Seattle Treatment Education Project
Triple Combination Therapy Including Indinavir Is Effective in Advanced AIDS (January 1997)
[Archived Article]
In The 4th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Two Year Follow-Up of Patients Treated With Indinavir (Crixivan) (January 1997)
[Archived Article]
In The 4th Conference on Retroviruses and Opportunistic Infections, from The Body PRO

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.